ADVERTISEMENT
Mexico
Country
Prestige Biopharma has picked Biosidus to manufacture and export its Tuznue biosimilar rival to Herceptin across four Latin American countries.
The latest report also demonstrates the EU’s trade relationships around the world, including with the US.
Two of Latin America’s biggest regulators have signed a memorandum of understanding to deepen cooperation and improve access to medicines.
Mexico’s drugs regulator will be able to grant quicker drug approvals based on decisions issued by World Health Organization listed authorities and founding ICH members.
Roberto Khoury, Perrigo’s international lead for a year, moves to CCO while his counterpart for the Americas region appointed in September 2023, Catherine "Triona" Schmelter, is leaving with her post eliminated in the firm’s changes.
Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.
Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.
Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.
The US administration added another layer of confusion after its overnight pronouncements on Mexican tariffs. For medtech, the uncertainty remains, and while the potential impact on the industry might still seem to be a simple question of bilateral trade math, which in itself is huge, the ramifications go even deeper – and wider, writes Bernard Murphy.
The president says 4 March would mark the start of tariffs he initially intended to take effect on 1 February before allowing a delay for Mexico and Canada to implement border security to help curb illegal entry by immigrants and fentanyl smuggling.
Lupin has added two ADHD drugs to its Canadian portfolio, while also signing multiple branded deals in other global markets.
Doubling down on its Latin American strategy, Zydus has managed to snap up a second biosimilar approval in Mexico, paving the way for future launches.